1.27
+0(+0.00%)
Currency In USD
| Previous Close | 1.27 |
| Open | 1.27 |
| Day High | 1.27 |
| Day Low | 1.27 |
| 52-Week High | 22.5 |
| 52-Week Low | 0.92 |
| Volume | 1.59M |
| Average Volume | 634,437 |
| Market Cap | 77.5M |
| PE | -1.41 |
| EPS | -0.9 |
| Moving Average 50 Days | 1.27 |
| Moving Average 200 Days | 3.58 |
| Change | 0 |
Data not available
IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right
GlobeNewswire Inc.
Jul 01, 2025 12:58 PM GMT
MOUNTAIN VIEW, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company that has focused on developing engineered IgM-based therapeutic antibodies, today announced that it has entered into a definitive
IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs
GlobeNewswire Inc.
Jan 09, 2025 6:00 PM GMT
– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December 31, 2024 – MOUNTAIN VIEW, Calif., Jan. 09, 202
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Nov 08, 2024 12:00 PM GMT
– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for generalized myasthenia gravis by yea